Uncategorized
TANZANITE study: No re-treatments required with triamcinolone acetonide formulation after 3 months
A majority of patients treated with a proprietary form of triamcinolone acetonide in combination with aflibercept required no additional treatments over 3 months compared with patients treated with aflibercept alone, Clearside Biomedical announced in a press release.The phase 2 TANZANITE clinical trial included 46 treatment-naïve patients with macular edema associated with retinal vein occlusion who were randomized to receive suprachoroidally administered Zuprata (triamcinolone acetonide, Clearside) in combination with intravitreally administered Eylea (aflibercept, Regeneron) or Eylea alone.